{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T15:39:43Z","timestamp":1768750783650,"version":"3.49.0"},"reference-count":241,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.intimp.2020.107245","type":"journal-article","created":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T03:25:25Z","timestamp":1606793125000},"page":"107245","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Interferon-inducer antivirals: Potential candidates to combat COVID-19"],"prefix":"10.1016","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8175-301X","authenticated-orcid":false,"given":"Ashkan","family":"Bagheri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyed Mohammad Iman","family":"Moezzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pouria","family":"Mosaddeghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sadra","family":"Nadimi Parashkouhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyed Mostafa","family":"Fazel Hoseini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0305-611X","authenticated-orcid":false,"given":"Fatemeh","family":"Badakhshan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manica","family":"Negahdaripour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.intimp.2020.107245_b0005","doi-asserted-by":"crossref","first-page":"7441","DOI":"10.1128\/JVI.73.9.7441-7452.1999","article-title":"Mapping of the coronavirus membrane protein domains involved in interaction with the spike protein","volume":"73","author":"De Haan","year":"1999","journal-title":"J. Virol."},{"issue":"10","key":"10.1016\/j.intimp.2020.107245_b0010","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.tim.2013.05.005","article-title":"Interspecies transmission and emergence of novel viruses: lessons from bats and birds","volume":"21","author":"Chan","year":"2013","journal-title":"Trends Microbiol."},{"issue":"13","key":"10.1016\/j.intimp.2020.107245_b0015","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention","volume":"323","author":"Wu","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.intimp.2020.107245_b0020","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.3389\/fimmu.2018.02061","article-title":"The dual nature of type I and type II interferons","volume":"9","author":"Lee","year":"2018","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2020.107245_b0025","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nri3806","article-title":"Regulation of antiviral T cell responses by type I interferons","volume":"15","author":"Crouse","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2020.107245_b0030","article-title":"Impaired type I interferon activity and exacerbated inflammatory responses in severe Covid-19 patients","author":"Hadjadj","year":"2020","journal-title":"MedRxiv"},{"key":"10.1016\/j.intimp.2020.107245_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.04.026","article-title":"Imbalanced host response to SARS-CoV-2 drives development of COVID-19","author":"Blanco-Melo","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2020.107245_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106924","article-title":"Immunotherapeutic approaches to curtail COVID-19","author":"Owji","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2020.107245_b0045","article-title":"Dysregulation of immune response in patients with COVID-19 in Wuhan, China","author":"Qin","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.intimp.2020.107245_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.chom.2020.05.008","article-title":"Type I and Type III interferons-induction, signaling, evasion, and application to combat COVID-19","author":"Park","year":"2020","journal-title":"Cell Host Microbe"},{"issue":"3","key":"10.1016\/j.intimp.2020.107245_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.chom.2020.07.005","article-title":"Retrospective multicenter cohort study shows early interferon therapy is associated with favorable clinical responses in COVID-19 patients","volume":"28","author":"Wang","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.intimp.2020.107245_b0060","article-title":"Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial","author":"Monk","year":"2020","journal-title":"Lancet Resp. Med."},{"issue":"1","key":"10.1016\/j.intimp.2020.107245_b0065","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1080\/22221751.2020.1736644","article-title":"A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence: lessons from other pathogenic viruses","volume":"9","author":"Fung","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"10.1016\/j.intimp.2020.107245_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.mehy.2020.110111","article-title":"Inflammation: a bridge between diabetes and COVID-19, and possible management with sitagliptin","volume":"143","author":"Mozafari","year":"2020","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.intimp.2020.107245_b0075","article-title":"SARS-CoV-2 is sensitive to type I interferon pretreatment","author":"Lokugamage","year":"2020","journal-title":"BioRxiv"},{"key":"10.1016\/j.intimp.2020.107245_b0080","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.exger.2017.08.019","article-title":"Reduced dynamic range of antiviral innate immune responses in aging","volume":"107","author":"Molony","year":"2018","journal-title":"Exp. Gerontol."},{"key":"10.1016\/j.intimp.2020.107245_b0085","doi-asserted-by":"crossref","unstructured":"A. Maiti, African-American Population Is More Vulnerable to Sars-CoV2 Infection and IFN-Beta Supplement Can Be An Effective Treatment. Available at SSRN 3566710, 2020. Hhtps:\/\/doi.org\/10.1007\/s00251-020-01174-6.","DOI":"10.2139\/ssrn.3566710"},{"key":"10.1016\/j.intimp.2020.107245_b0090","first-page":"1","article-title":"Harnessing the non-specific immunogenic effects of available vaccines to combat COVID-19","volume":"13","author":"Mosaddeghi","year":"2020","journal-title":"Hum. Vaccin. Immunother."},{"issue":"2","key":"10.1016\/j.intimp.2020.107245_b0095","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/cmi.2013.61","article-title":"Suppression of innate antiviral response by severe acute respiratory syndrome coronavirus M protein is mediated through the first transmembrane domain","volume":"11","author":"Siu","year":"2014","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.intimp.2020.107245_b0100","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/bs.aivir.2016.08.006","article-title":"Interaction of SARS and MERS coronaviruses with the antiviral interferon response","volume":"96","author":"Kindler","year":"2016","journal-title":"Adv. Virus Res."},{"issue":"9","key":"10.1016\/j.intimp.2020.107245_b0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.0060226","article-title":"SARS-coronavirus replication is supported by a reticulovesicular network of modified endoplasmic reticulum","volume":"6","author":"Knoops","year":"2008","journal-title":"PLoS Biol."},{"issue":"4","key":"10.1016\/j.intimp.2020.107245_b0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000863","article-title":"In vitro reconstitution of SARS-coronavirus mRNA cap methylation","volume":"6","author":"Bouvet","year":"2010","journal-title":"PLoS Pathog."},{"issue":"9","key":"10.1016\/j.intimp.2020.107245_b0115","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1073\/pnas.0808790106","article-title":"Functional screen reveals SARS coronavirus nonstructural protein nsp14 as a novel cap N7 methyltransferase","volume":"106","author":"Chen","year":"2009","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"12","key":"10.1016\/j.intimp.2020.107245_b0120","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s13238-013-3096-8","article-title":"The structural and accessory proteins M, ORF 4a, ORF 4b, and ORF 5 of Middle East respiratory syndrome coronavirus (MERS-CoV) are potent interferon antagonists","volume":"4","author":"Yang","year":"2013","journal-title":"Protein Cell"},{"issue":"1","key":"10.1016\/j.intimp.2020.107245_b0125","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11262-010-0544-x","article-title":"SARS-CoV nucleocapsid protein antagonizes IFN-\u03b2 response by targeting initial step of IFN-\u03b2 induction pathway, and its C-terminal region is critical for the antagonism","volume":"42","author":"Lu","year":"2011","journal-title":"Virus Genes"},{"issue":"2","key":"10.1016\/j.intimp.2020.107245_b0130","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1128\/JVI.01782-06","article-title":"Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and nucleocapsid proteins function as interferon antagonists","volume":"81","author":"Kopecky-Bromberg","year":"2007","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.intimp.2020.107245_b0135","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00258-16","article-title":"Middle East respiratory syndrome coronavirus NS4b protein inhibits host RNase L activation","volume":"7","author":"Thornbrough","year":"2016","journal-title":"MBio"},{"issue":"21","key":"10.1016\/j.intimp.2020.107245_b0140","doi-asserted-by":"crossref","first-page":"11620","DOI":"10.1128\/JVI.00702-07","article-title":"Severe acute respiratory syndrome coronavirus evades antiviral signaling: role of nsp1 and rational design of an attenuated strain","volume":"81","author":"Wathelet","year":"2007","journal-title":"J. Virol."},{"issue":"6515","key":"10.1016\/j.intimp.2020.107245_b0145","doi-asserted-by":"crossref","DOI":"10.1126\/science.abd4570","article-title":"Inborn errors of type I IFN immunity in patients with life-threatening COVID-19","volume":"370","author":"Zhang","year":"2020","journal-title":"Science"},{"issue":"6515","key":"10.1016\/j.intimp.2020.107245_b0150","doi-asserted-by":"crossref","DOI":"10.1126\/science.abd4585","article-title":"Autoantibodies against type I IFNs in patients with life-threatening COVID-19","volume":"370","author":"Bastard","year":"2020","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.intimp.2020.107245_b0155","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.cytogfr.2014.07.015","article-title":"Interferons: success in anti-viral immunotherapy","volume":"25","author":"Lin","year":"2014","journal-title":"Cytokine Growth Factor Rev."},{"issue":"2","key":"10.1016\/j.intimp.2020.107245_b0160","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.chom.2016.01.007","article-title":"Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice","volume":"19","author":"Channappanavar","year":"2016","journal-title":"Cell Host Microbe"},{"issue":"1","key":"10.1016\/j.intimp.2020.107245_b0165","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.intimp.2020.107245_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2020.02.018","article-title":"Discovery and development of safe-in-man broad-spectrum antiviral agents","author":"Andersen","year":"2020","journal-title":"Int. J. Infect. Dis."},{"issue":"3","key":"10.1016\/j.intimp.2020.107245_b0175","first-page":"155","article-title":"A world of changes: the inheritance of COVID-19","volume":"45","author":"Negahdaripour","year":"2020","journal-title":"Iran. J. Med. Sci."},{"issue":"4","key":"10.1016\/j.intimp.2020.107245_b0180","first-page":"231","article-title":"The rise and fall in therapeutic candidates for COVID-19","volume":"45","author":"Negahdaripour","year":"2020","journal-title":"Iran. J. Med. Sci."},{"issue":"D1","key":"10.1016\/j.intimp.2020.107245_b0185","doi-asserted-by":"crossref","first-page":"D1102","DOI":"10.1093\/nar\/gky1033","article-title":"PubChem 2019 update: improved access to chemical data","volume":"47","author":"Kim","year":"2019","journal-title":"Nucleic Acids Res."},{"issue":"D1","key":"10.1016\/j.intimp.2020.107245_b0190","doi-asserted-by":"crossref","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","article-title":"DrugBank 5.0: a major update to the DrugBank database for 2018","volume":"46","author":"Wishart","year":"2018","journal-title":"Nucleic Acids Res."},{"issue":"12","key":"10.1016\/j.intimp.2020.107245_b0195","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00394-19","article-title":"Azithromycin protects against zika virus infection by upregulating virus-induced Type I and III interferon responses","volume":"63","author":"Li","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.intimp.2020.107245_b0200","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1183\/09031936.00095809","article-title":"Azithromycin induces anti-viral responses in bronchial epithelial cells","volume":"36","author":"Gielen","year":"2010","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.intimp.2020.107245_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","volume":"56","author":"Gautret","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.intimp.2020.107245_b0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmaid.2020.101663","article-title":"Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study","volume":"34","author":"Gautret","year":"2020","journal-title":"Travel Med. Infect. Dis."},{"issue":"5","key":"10.1016\/j.intimp.2020.107245_b0215","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41564-018-0138-2","article-title":"Topical application of aminoglycoside antibiotics enhances host resistance to viral infections in a microbiota-independent manner","volume":"3","author":"Gopinath","year":"2018","journal-title":"Nat. Microbiol."},{"issue":"11","key":"10.1016\/j.intimp.2020.107245_b0220","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1039\/c2mb25333j","article-title":"Aminoglycoside antibiotics bind to the influenza A virus RNA promoter","volume":"8","author":"Kim","year":"2012","journal-title":"Mol. BioSyst."},{"key":"10.1016\/j.intimp.2020.107245_b0225","unstructured":"https:\/\/www.drugs.com\/."},{"key":"10.1016\/j.intimp.2020.107245_b0230","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04341493."},{"issue":"5","key":"10.1016\/j.intimp.2020.107245_b0235","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01706-19","article-title":"Astrovirus replication is inhibited by nitazoxanide in vitro and in vivo","volume":"94","author":"Hargest","year":"2020","journal-title":"J. Virol."},{"issue":"5","key":"10.1016\/j.intimp.2020.107245_b0240","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1053\/j.gastro.2009.07.056","article-title":"The anti-hepatitis C agent nitazoxanide induces phosphorylation of eukaryotic initiation factor 2\u03b1 via protein kinase activated by double-stranded RNA activation","volume":"137","author":"Elazar","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.intimp.2020.107245_b0245","doi-asserted-by":"crossref","unstructured":"M. Kelleni, Nitazoxanide\/Azithromycin combination for COVID-19: a suggested new protocol for COVID-19 early management, 2020.","DOI":"10.20944\/preprints202004.0432.v1"},{"issue":"5","key":"10.1016\/j.intimp.2020.107245_b0250","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1021\/acsinfecdis.0c00052","article-title":"Broad spectrum antiviral agent niclosamide and its therapeutic potential","volume":"6","author":"Xu","year":"2020","journal-title":"ACS Infect. Dis."},{"issue":"13","key":"10.1016\/j.intimp.2020.107245_b0255","doi-asserted-by":"crossref","first-page":"4469","DOI":"10.1021\/jm050184y","article-title":"Discovery of potent anilide inhibitors against the severe acute respiratory syndrome 3CL protease","volume":"48","author":"Shie","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.intimp.2020.107245_b0260","unstructured":"https:\/\/clinicaltrials.gov\/."},{"key":"10.1016\/j.intimp.2020.107245_b0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.mehy.2020.109765","article-title":"Plausible mechanisms of Niclosamide as an antiviral agent against COVID-19","volume":"140","author":"Pindiprolu","year":"2020","journal-title":"Med. Hypotheses"},{"issue":"1","key":"10.1016\/j.intimp.2020.107245_b0270","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1080\/22221751.2018.1559709","article-title":"The clinically licensed antifungal drug itraconazole inhibits influenza virus in vitro and in vivo","volume":"8","author":"Schloer","year":"2019","journal-title":"Emerg. Microbes Infect."},{"issue":"11","key":"10.1016\/j.intimp.2020.107245_b0275","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0027866","article-title":"Ribavirin enhances IFN-\u03b1 signalling and MxA expression: a novel immune modulation mechanism during treatment of HCV","volume":"6","author":"Stevenson","year":"2011","journal-title":"PLoS ONE"},{"issue":"9","key":"10.1016\/j.intimp.2020.107245_b0280","article-title":"Ribavirin enhances the action of interferon-\u03b1 against hepatitis C virus by promoting the p53 activity through the ERK1\/2 pathway","volume":"7","author":"Liu","year":"2012","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.intimp.2020.107245_b0285","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1177\/1087057113496848","article-title":"High-throughput screening normalized to biological response: application to antiviral drug discovery","volume":"19","author":"Patel","year":"2014","journal-title":"J. Biomol. Screen."},{"issue":"5","key":"10.1016\/j.intimp.2020.107245_b0290","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0036594","article-title":"High throughput screening for small molecule enhancers of the interferon signaling pathway to drive next-generation antiviral drug discovery","volume":"7","author":"Patel","year":"2012","journal-title":"PLoS ONE"},{"issue":"11","key":"10.1016\/j.intimp.2020.107245_b0295","doi-asserted-by":"crossref","first-page":"3480","DOI":"10.3390\/ijms19113480","article-title":"Anthracyclines as topoisomerase II poisons: from early studies to new perspectives","volume":"19","author":"Marinello","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2020.107245_b0300","first-page":"1","article-title":"Identification of potential inhibitors of SARS-COV-2 endoribonuclease (EndoU) from FDA approved drugs: a drug repurposing approach to find therapeutics for COID19","author":"Chandra","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"6","key":"10.1016\/j.intimp.2020.107245_b0305","doi-asserted-by":"crossref","first-page":"e02272","DOI":"10.1128\/mBio.02272-18","article-title":"Repurposing estrogen receptor antagonists for the treatment of infectious disease","volume":"9","author":"Montoya","year":"2018","journal-title":"MBio"},{"key":"10.1016\/j.intimp.2020.107245_b0310","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.lfs.2017.10.027","article-title":"Gefitinib and pyrrolidine dithiocarbamate decrease viral replication and cytokine production in dengue virus infected human monocyte cultures","volume":"191","author":"Duran","year":"2017","journal-title":"Life Sci."},{"issue":"10","key":"10.1016\/j.intimp.2020.107245_b0315","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.3390\/ijms18102227","article-title":"The MEK inhibitors trametinib and cobimetinib induce a type I interferon response in human keratinocytes","volume":"18","author":"Lulli","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.intimp.2020.107245_b0320","first-page":"361","article-title":"Middle East respiratory syndrome-coronavirus (MERS-CoV): an updated overview and pharmacotherapeutics","volume":"5","author":"Pillaiyar","year":"2015","journal-title":"Med chem"},{"key":"10.1016\/j.intimp.2020.107245_b0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.bj.2020.05.001","article-title":"Artificial intelligence approach fighting COVID-19 with repurposing drugs","author":"Ke","year":"2020","journal-title":"Biomed. J."},{"issue":"42","key":"10.1016\/j.intimp.2020.107245_b0330","doi-asserted-by":"crossref","first-page":"35324","DOI":"10.1074\/jbc.M112.392142","article-title":"Obatoclax, saliphenylhalamide, and gemcitabine inhibit influenza a virus infection","volume":"287","author":"Denisova","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.intimp.2020.107245_b0335","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1177\/0956462419839520","article-title":"Antiviral activity of sirolimus in an HIV-positive kidney transplant recipient","volume":"30","author":"Alfano","year":"2019","journal-title":"Int. J. STD AIDS"},{"issue":"1","key":"10.1016\/j.intimp.2020.107245_b0340","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41421-020-0153-3","article-title":"Network-based drug repurposing for novel coronavirus 2019-nCoV\/SARS-CoV-2","volume":"6","author":"Zhou","year":"2020","journal-title":"Cell Discov."},{"issue":"6","key":"10.1016\/j.intimp.2020.107245_b0345","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1002\/hep.25562","article-title":"Mycophenolic acid augments interferon-stimulated gene expression and inhibits hepatitis C Virus infection in vitro and in vivo","volume":"55","author":"Pan","year":"2012","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.intimp.2020.107245_b0350","doi-asserted-by":"crossref","first-page":"497","DOI":"10.5114\/aoms.2020.94046","article-title":"State-of-the-art tools to identify druggable protein ligand of SARS-CoV-2","volume":"16","author":"Azeez","year":"2020","journal-title":"Arch. Med. Sci."},{"issue":"5","key":"10.1016\/j.intimp.2020.107245_b0355","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/hep.22215","article-title":"Acetylsalicylic acid inhibits hepatitis C virus RNA and protein expression through cyclooxygenase 2 signaling pathways","volume":"47","author":"Trujillo-Murillo","year":"2008","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.intimp.2020.107245_b0360","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.cyto.2003.08.014","article-title":"In vitro effect of indomethacin and interferon-\u03b1 on Th1 and Th2 cytokine synthesis in patients with chronic hepatitis C","volume":"26","author":"Andreone","year":"2004","journal-title":"Cytokine"},{"key":"10.1016\/j.intimp.2020.107245_b0365","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.13535","article-title":"Indomethacin and resveratrol as potential treatment adjuncts for SARS-CoV-2\/COVID-19","author":"Marinella","year":"2020","journal-title":"Int. J. Clin. Pract."},{"issue":"54","key":"10.1016\/j.intimp.2020.107245_b0370","doi-asserted-by":"crossref","first-page":"91928","DOI":"10.18632\/oncotarget.20248","article-title":"Metformin activates type I interferon signaling against HCV via activation of adenosine monophosphate-activated protein kinase","volume":"8","author":"Tsai","year":"2017","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.intimp.2020.107245_b0375","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1128\/JVI.02649-13","article-title":"Beta interferon regulation of glucose metabolism is PI3K\/Akt dependent and important for antiviral activity against coxsackievirus B3","volume":"88","author":"Burke","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.intimp.2020.107245_b0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2020.108146","article-title":"Should anti-diabetic medications be reconsidered amid COVID-19 pandemic?","volume":"163","author":"Pal","year":"2020","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.intimp.2020.107245_b0385","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.antiviral.2014.08.002","article-title":"Fluoxetine a novel anti-hepatitis C virus agent via ROS-, JNK-, and PPAR\u03b2\/\u03b3-dependent pathways","volume":"110","author":"Young","year":"2014","journal-title":"Antiviral Res."},{"issue":"8","key":"10.1016\/j.intimp.2020.107245_b0390","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1093\/jac\/dku091","article-title":"The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry","volume":"69","author":"Gehring","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"issue":"4","key":"10.1016\/j.intimp.2020.107245_b0395","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/ehjcvp\/pvaa042","article-title":"Statin therapy in COVID-19 infection","volume":"6","author":"Castiglione","year":"2020","journal-title":"Eur. Heart J.\u2014Cardiovasc. Pharmacother."},{"issue":"8","key":"10.1016\/j.intimp.2020.107245_b0400","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2217\/fvl.12.71","article-title":"Effect of statin treatments on highly pathogenic avian influenza H5N1, seasonal and H1N1pdm09 virus infections in BALB\/c mice","volume":"7","author":"Kumaki","year":"2012","journal-title":"Future Virol."},{"issue":"6","key":"10.1016\/j.intimp.2020.107245_b0405","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.3892\/mmr.2014.2076","article-title":"Protective effect of fluvastatin on influenza virus infection","volume":"9","author":"Peng","year":"2014","journal-title":"Mol. Med. Rep."},{"issue":"2","key":"10.1016\/j.intimp.2020.107245_b0410","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00705-014-2302-1","article-title":"Caffeine inhibits hepatitis C virus replication in vitro","volume":"160","author":"Batista","year":"2015","journal-title":"Arch. Virol."},{"issue":"5","key":"10.1016\/j.intimp.2020.107245_b0415","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0019705","article-title":"Glycyrrhizin exerts antioxidative effects in H5N1 influenza A virus-infected cells and inhibits virus replication and pro-inflammatory gene expression","volume":"6","author":"Michaelis","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.intimp.2020.107245_b0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105995","article-title":"Pharmacological perspective: glycyrrhizin may be an efficacious therapeutic agent for COVID-19","author":"Luo","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.intimp.2020.107245_b0425","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/2039897","article-title":"In vivo interrelationship between insulin resistance and interferon gamma production: protective and therapeutic effect of berberine","author":"Mahmoud","year":"2016","journal-title":"Evidence-Based Complem. Alternative Med."},{"issue":"6","key":"10.1016\/j.intimp.2020.107245_b0430","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1080\/13102818.2015.1069172","article-title":"Immunomodulatory effect of Berberis vulgaris extracts on murine splenocytes and enrichment of dendritic cells in vitro","volume":"29","author":"Aziz","year":"2015","journal-title":"Biotechnol. Biotechnol. Equip."},{"issue":"1","key":"10.1016\/j.intimp.2020.107245_b0435","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep28698","article-title":"Azithromycin induces anti-viral effects in cultured bronchial epithelial cells from COPD patients","volume":"6","author":"Menzel","year":"2016","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.intimp.2020.107245_b0440","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/ja.2013.132","article-title":"Leucomycin A 3, a 16-membered macrolide antibiotic, inhibits influenza A virus infection and disease progression","volume":"67","author":"Sugamata","year":"2014","journal-title":"J. Antibiotics"},{"issue":"4","key":"10.1016\/j.intimp.2020.107245_b0445","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ijantimicag.2018.12.009","article-title":"Spiramycin and azithromycin, safe for administration to children, exert antiviral activity against enterovirus A71 in vitro and in vivo","volume":"53","author":"Zeng","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.intimp.2020.107245_b0450","first-page":"1","article-title":"Assessment of efficacy of Oseltamivir-Azithromycin combination therapy in prevention of Influenza-A (H1N1) pdm09 infection complications and rapidity of symptoms relief","author":"Ishaqui","year":"2020","journal-title":"Expert Rev. Respiratory Med."},{"issue":"2","key":"10.1016\/j.intimp.2020.107245_b0455","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1183\/09031936.00102014","article-title":"Novel antiviral properties of azithromycin in cystic fibrosis airway epithelial cells","volume":"45","author":"Sch\u00f6gler","year":"2015","journal-title":"Eur. Respir. J."},{"issue":"19","key":"10.1016\/j.intimp.2020.107245_b0460","doi-asserted-by":"crossref","first-page":"31601","DOI":"10.18632\/oncotarget.16364","article-title":"Azithromycin augments rhinovirus-induced IFN\u03b2 via cytosolic MDA5 in experimental models of asthma exacerbation","volume":"8","author":"Menzel","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.intimp.2020.107245_b0465","first-page":"1","article-title":"CD147 as a Target for COVID-19 treatment: suggested effects of azithromycin and stem cell engagement","author":"Ulrich","year":"2020","journal-title":"Stem Cell Rev. Reports"},{"key":"10.1016\/j.intimp.2020.107245_b0470","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.intimp.2016.09.012","article-title":"Azithromycin modulates immune response of human monocyte-derived dendritic cells and CD4+ T cells","volume":"40","author":"Lin","year":"2016","journal-title":"Int. Immunopharmacol."},{"issue":"6","key":"10.1016\/j.intimp.2020.107245_b0475","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jmii.2019.10.001","article-title":"Azithromycin suppresses Th1-and Th2-related chemokines IP-10\/MDC in human monocytic cell line","volume":"52","author":"Kuo","year":"2019","journal-title":"J. Microbiol. Immunol. Infect."},{"issue":"5","key":"10.1016\/j.intimp.2020.107245_b0480","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/ppul.23956","article-title":"Role of prophylactic azithromycin to reduce airway inflammation and mortality in a RSV mouse infection model","volume":"53","author":"Mosquera","year":"2018","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.intimp.2020.107245_b0485","doi-asserted-by":"crossref","DOI":"10.1002\/cpt.1857","article-title":"Clinical pharmacology perspectives on the antiviral activity of azithromycin and use in COVID-19","author":"Damle","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.intimp.2020.107245_b0490","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2020.104228","article-title":"In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect","author":"Andreani","year":"2020","journal-title":"Microb. Pathog."},{"key":"10.1016\/j.intimp.2020.107245_b0495","article-title":"No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection","volume":"10","author":"Molina","year":"2020","journal-title":"Med. Mal. Infect."},{"issue":"3","key":"10.1016\/j.intimp.2020.107245_b0500","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0166-3542(91)90064-X","article-title":"Inhibition of influenza A virus replication by a kanamycin derivative","volume":"15","author":"Yamada","year":"1991","journal-title":"Antiviral Res."},{"issue":"16","key":"10.1016\/j.intimp.2020.107245_b0505","doi-asserted-by":"crossref","first-page":"1900288","DOI":"10.1002\/advs.201900288","article-title":"Lipidic aminoglycoside derivatives: a new class of immunomodulators inducing a potent innate immune stimulation","volume":"6","author":"Colombani","year":"2019","journal-title":"Adv. Sci. (Weinh)"},{"issue":"1","key":"10.1016\/j.intimp.2020.107245_b0510","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1586\/14787210.2.1.43","article-title":"Nitazoxanide: a new broad spectrum antiparasitic agent","volume":"2","author":"White","year":"2004","journal-title":"Expert Rev. Anti-infective Therapy"},{"issue":"5","key":"10.1016\/j.intimp.2020.107245_b0515","doi-asserted-by":"crossref","first-page":"1002691","DOI":"10.1371\/journal.ppat.1002691","article-title":"Nitazoxanide stimulates autophagy and inhibits mTORC1 signaling and intracellular proliferation of Mycobacterium tuberculosis","volume":"8","author":"Lam","year":"2012","journal-title":"PLoS Pathog."},{"issue":"1","key":"10.1016\/j.intimp.2020.107245_b0520","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.intimp.2012.03.002","article-title":"Nitazoxanide suppresses IL-6 production in LPS-stimulated mouse macrophages and TG-injected mice","volume":"13","author":"Hong","year":"2012","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2020.107245_b0525","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.isci.2019.07.003","article-title":"The FDA-approved oral drug nitazoxanide amplifies host antiviral responses and inhibits Ebola virus","volume":"19","author":"Jasenosky","year":"2019","journal-title":"iScience"},{"issue":"3","key":"10.1016\/j.intimp.2020.107245_b0530","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jiph.2016.04.001","article-title":"Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus","volume":"9","author":"Rossignol","year":"2016","journal-title":"J. Infect. Public Health"},{"key":"10.1016\/j.intimp.2020.107245_b0535","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.antiviral.2014.07.014","article-title":"Nitazoxanide: a first-in-class broad-spectrum antiviral agent","volume":"110","author":"Rossignol","year":"2014","journal-title":"Antiviral Res."},{"issue":"7","key":"10.1016\/j.intimp.2020.107245_b0540","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1473-3099(14)70717-0","article-title":"Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b\/3 trial","volume":"14","author":"Haffizulla","year":"2014","journal-title":"Lancet. Infect. Dis"},{"issue":"2","key":"10.1016\/j.intimp.2020.107245_b0545","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0163-7258(82)90064-X","article-title":"The biology and toxicology of molluscicides, Bayluscide","volume":"19","author":"Andrews","year":"1982","journal-title":"Pharmacol. Therap."},{"issue":"4","key":"10.1016\/j.intimp.2020.107245_b0550","doi-asserted-by":"crossref","first-page":"550","DOI":"10.7326\/0003-4819-102-4-550","article-title":"Niclosamide therapy for tapeworm infections","volume":"102","author":"Pearson","year":"1985","journal-title":"Ann. Internal Med."},{"key":"10.1016\/j.intimp.2020.107245_b0555","unstructured":"Selection, W.E.C.o.t., U.o.E. Medicines, and W.H. Organization, The Selection and Use of Essential Medicines, vol. 950, 2008, World Health Organization. ISSN 05123054."},{"issue":"5185","key":"10.1016\/j.intimp.2020.107245_b0560","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1038\/2211016a0","article-title":"Mechanism of action of reagents that uncouple oxidative phosphorylation","volume":"221","author":"Weinbach","year":"1969","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2020.107245_b0565","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cellsig.2017.04.001","article-title":"Niclosamide: beyond an antihelminthic drug","volume":"41","author":"Chen","year":"2018","journal-title":"Cell. Signal."},{"issue":"50","key":"10.1016\/j.intimp.2020.107245_b0570","doi-asserted-by":"crossref","first-page":"35769","DOI":"10.1074\/jbc.M113.511212","article-title":"Suppression of lysosome function induces autophagy via a feedback down-regulation of MTOR complex 1 (MTORC1) activity","volume":"288","author":"Li","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"3\u20134","key":"10.1016\/j.intimp.2020.107245_b0575","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00011-015-0801-5","article-title":"Inhibitory effects of niclosamide on inflammation and migration of fibroblast-like synoviocytes from patients with rheumatoid arthritis","volume":"64","author":"Liang","year":"2015","journal-title":"Inflamm. Res."},{"issue":"9","key":"10.1016\/j.intimp.2020.107245_b0580","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1021\/ml100146z","article-title":"Identification of niclosamide as a new small-molecule inhibitor of the STAT3 signaling pathway","volume":"1","author":"Ren","year":"2010","journal-title":"ACS Med. Chem. Lett."},{"issue":"7","key":"10.1016\/j.intimp.2020.107245_b0585","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1128\/AAC.48.7.2693-2696.2004","article-title":"Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide","volume":"48","author":"Wu","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"issue":"17","key":"10.1016\/j.intimp.2020.107245_b0590","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1021\/jm070295s","article-title":"Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus","volume":"50","author":"Wen","year":"2007","journal-title":"J. Med. Chem."},{"issue":"5626","key":"10.1016\/j.intimp.2020.107245_b0595","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1126\/science.1085658","article-title":"Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs","volume":"300","author":"Anand","year":"2003","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.intimp.2020.107245_b0600","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0006-291X(03)01342-1","article-title":"Binding mechanism of coronavirus main proteinase with ligands and its implication to drug design against SARS","volume":"308","author":"Chou","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.intimp.2020.107245_b0605","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-13659-4","article-title":"SKP2 attenuates autophagy through Beclin1-ubiquitination and its inhibition reduces MERS-Coronavirus infection","volume":"10","author":"Gassen","year":"2019","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.intimp.2020.107245_b0610","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1136\/gutjnl-2014-309011","article-title":"Ribavirin restores IFNalpha responsiveness in HCV-infected livers by epigenetic remodelling at interferon stimulated genes","volume":"65","author":"Testoni","year":"2016","journal-title":"Gut"},{"issue":"9","key":"10.1016\/j.intimp.2020.107245_b0615","article-title":"Ribavirin enhances the action of interferon-alpha against hepatitis C virus by promoting the p53 activity through the ERK1\/2 pathway","volume":"7","author":"Liu","year":"2012","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.intimp.2020.107245_b0620","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.antiviral.2006.03.001","article-title":"Enhancement of the infectivity of SARS-CoV in BALB\/c mice by IMP dehydrogenase inhibitors, including ribavirin","volume":"71","author":"Barnard","year":"2006","journal-title":"Antiviral Res."},{"key":"10.1016\/j.intimp.2020.107245_b0625","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.25798","article-title":"Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID-19","author":"Khalili","year":"2020","journal-title":"J. Med. Virol."},{"issue":"4","key":"10.1016\/j.intimp.2020.107245_b0630","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.bbrc.2004.11.128","article-title":"Ribavirin and interferon-beta synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines","volume":"326","author":"Morgenstern","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.intimp.2020.107245_b0635","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117592","article-title":"Ribavirin, remdesivir, sofosbuvir, galidesivir, and tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study","volume":"253","author":"Elfiky","year":"2020","journal-title":"Life Sci."},{"issue":"6","key":"10.1016\/j.intimp.2020.107245_b0640","first-page":"2307","article-title":"The pathogenetic mechanism of anthracycline-induced palmar-plantar erythrodysesthesia","volume":"29","author":"Martschick","year":"2009","journal-title":"Anticancer Res."},{"issue":"5","key":"10.1016\/j.intimp.2020.107245_b0645","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41564-018-0152-4","article-title":"New activities for old antibiotics","volume":"3","author":"Cohen","year":"2018","journal-title":"Nat. Microbiol."},{"issue":"17","key":"10.1016\/j.intimp.2020.107245_b0650","doi-asserted-by":"crossref","first-page":"5010","DOI":"10.1158\/1078-0432.CCR-06-1136","article-title":"The science of selective estrogen receptor modulators: concept to clinical practice","volume":"12","author":"Jordan","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.intimp.2020.107245_b0655","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nm0496-381","article-title":"Tamoxifen: teaching an old drug new tricks?","volume":"2","author":"Grainger","year":"1996","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.intimp.2020.107245_b0660","doi-asserted-by":"crossref","DOI":"10.3390\/ph12040142","article-title":"Tamoxifen protects from vesicular stomatitis virus infection","volume":"12","author":"Cham","year":"2019","journal-title":"Pharmaceuticals (Basel)"},{"issue":"14","key":"10.1016\/j.intimp.2020.107245_b0665","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1158\/1078-0432.CCR-17-2551","article-title":"Interferon-stimulated genes are involved in cross-resistance to radiotherapy in tamoxifen-resistant breast cancer","volume":"24","author":"Post","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.intimp.2020.107245_b0670","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.2165\/00003088-200544100-00005","article-title":"Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol","volume":"44","author":"Swaisland","year":"2005","journal-title":"Clin. Pharmacokinet."},{"issue":"2","key":"10.1016\/j.intimp.2020.107245_b0675","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.lungcan.2013.08.013","article-title":"Pharmacokinetic and pharmacodynamic study of Gefitinib in a mouse model of non-small-cell lung carcinoma with brain metastasis","volume":"82","author":"Chen","year":"2013","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.intimp.2020.107245_b0680","doi-asserted-by":"crossref","first-page":"712","DOI":"10.21037\/jtd.2019.12.106","article-title":"Knockdown of PLAT enhances the anticancer effect of gefitinib in non-small cell lung cancer","volume":"12","author":"Yan","year":"2020","journal-title":"J. Thorac Dis."},{"issue":"4","key":"10.1016\/j.intimp.2020.107245_b0685","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.jsps.2020.03.002","article-title":"Liraglutide attenuates gefitinib-induced cardiotoxicity and promotes cardioprotection through the regulation of MAPK\/NF-kappaB signaling pathways","volume":"28","author":"AlAsmari","year":"2020","journal-title":"Saudi Pharm. J."},{"issue":"5","key":"10.1016\/j.intimp.2020.107245_b0690","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1517\/14712598.2015.1026323","article-title":"Trametinib in the treatment of melanoma","volume":"15","author":"Thota","year":"2015","journal-title":"Expert. Opin. Biol. Ther."},{"issue":"9","key":"10.1016\/j.intimp.2020.107245_b0695","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1038\/s41375-020-0959-x","article-title":"COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus","volume":"34","author":"Scarfo","year":"2020","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.intimp.2020.107245_b0700","doi-asserted-by":"crossref","first-page":"893","DOI":"10.2165\/0002512-200825110-00001","article-title":"Quality-of-life assessment in phase III clinical trials of gemcitabine in non-small-cell lung cancer","volume":"25","author":"Reynolds","year":"2008","journal-title":"Drugs Aging"},{"key":"10.1016\/j.intimp.2020.107245_b0705","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejphar.2014.07.041","article-title":"Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer","volume":"741","author":"de Sousa Cavalcante","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.intimp.2020.107245_b0710","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.biocel.2014.12.010","article-title":"Inhibition of thymidylate synthase by 2\u2032, 2\u2032-difluoro-2\u2032-deoxycytidine (Gemcitabine) and its metabolite 2\u2032, 2\u2032-difluoro-2\u2032-deoxyuridine","volume":"60","author":"Honeywell","year":"2015","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"suppl_5","key":"10.1016\/j.intimp.2020.107245_b0715","doi-asserted-by":"crossref","first-page":"v7","DOI":"10.1093\/annonc\/mdj941","article-title":"Cellular pharmacology of gemcitabine","volume":"17","author":"Mini","year":"2006","journal-title":"Ann. Oncol."},{"issue":"70","key":"10.1016\/j.intimp.2020.107245_b0720","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.23258","article-title":"Gemcitabine, a broad-spectrum antiviral drug, suppresses enterovirus infections through innate immunity induced by the inhibition of pyrimidine biosynthesis and nucleotide depletion","volume":"8","author":"Lee","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.intimp.2020.107245_b0725","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1128\/MCB.16.1.369","article-title":"Roles of JAKs in activation of STATs and stimulation of c-fos gene expression by epidermal growth factor","volume":"16","author":"Leaman","year":"1996","journal-title":"Mol. Cell. Biol."},{"issue":"6","key":"10.1016\/j.intimp.2020.107245_b0730","doi-asserted-by":"crossref","first-page":"3946","DOI":"10.4049\/jimmunol.175.6.3946","article-title":"Critical roles for both STAT1-dependent and STAT1-independent pathways in the control of primary dengue virus infection in mice","volume":"175","author":"Shresta","year":"2005","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2020.107245_b0735","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3390\/v10040211","article-title":"Gemcitabine and nucleos (t) ide synthesis inhibitors are broad-spectrum antiviral drugs that activate innate immunity","volume":"10","author":"Shin","year":"2018","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.intimp.2020.107245_b0740","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1750-2187-7-12","article-title":"Understanding sensitivity to BH3 mimetics: ABT-737 as a case study to foresee the complexities of personalized medicine","volume":"7","author":"Stamelos","year":"2012","journal-title":"J. Mol. Signal."},{"issue":"9","key":"10.1016\/j.intimp.2020.107245_b0745","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1158\/0008-5472.CAN-07-1919","article-title":"Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax)","volume":"68","author":"Konopleva","year":"2008","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.intimp.2020.107245_b0750","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1158\/0008-5472.CAN-09-3535","article-title":"A Bax-mediated mechanism for obatoclax-induced apoptosis of cholangiocarcinoma cells","volume":"70","author":"Smoot","year":"2010","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.intimp.2020.107245_b0755","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2010.86","article-title":"Obatoclax induces Atg7-dependent autophagy independent of beclin-1 and BAX\/BAK","volume":"1","author":"McCoy","year":"2010","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.intimp.2020.107245_b0760","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.antiviral.2016.12.022","article-title":"Obatoclax, saliphenylhalamide and gemcitabine inhibit Zika virus infection in vitro and differentially affect cellular signaling, transcription and metabolism","volume":"139","author":"Kuivanen","year":"2017","journal-title":"Antiviral Res."},{"issue":"10","key":"10.1016\/j.intimp.2020.107245_b0765","doi-asserted-by":"crossref","first-page":"964","DOI":"10.3390\/v11100964","article-title":"Novel antiviral activities of obatoclax, emetine, niclosamide, brequinar, and homoharringtonine","volume":"11","author":"Andersen","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.intimp.2020.107245_b0770","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2019.104558","article-title":"The ReFRAME library as a comprehensive drug repurposing library to identify mammarenavirus inhibitors","volume":"169","author":"Kim","year":"2019","journal-title":"Antiviral Res."},{"issue":"3","key":"10.1016\/j.intimp.2020.107245_b0775","doi-asserted-by":"crossref","first-page":"e02227","DOI":"10.1128\/AAC.02227-16","article-title":"Obatoclax inhibits alphavirus membrane fusion by neutralizing the acidic environment of endocytic compartments","volume":"61","author":"Varghese","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"issue":"26","key":"10.1016\/j.intimp.2020.107245_b0780","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1056\/NEJMra033540","article-title":"Immunosuppressive drugs for kidney transplantation","volume":"351","author":"Halloran","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.intimp.2020.107245_b0785","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/s00467-016-3437-y","article-title":"Effect of mycophenolic acid in experimental, nontransplant glomerular diseases: new mechanisms beyond immune cells","volume":"32","author":"Hackl","year":"2017","journal-title":"Pediatric Nephrol."},{"issue":"4","key":"10.1016\/j.intimp.2020.107245_b0790","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/TP.0b013e3182247b5f","article-title":"Impact of mycophenolic acid and tacrolimus on Th17-related immune response","volume":"92","author":"Abadja","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.intimp.2020.107245_b0795","doi-asserted-by":"crossref","DOI":"10.3332\/ecancer.2020.1022","article-title":"Associations between immune-suppressive and stimulating drugs and novel COVID-19\u2014a systematic review of current evidence","volume":"14","author":"Russell","year":"2020","journal-title":"ecancermedicalscience"},{"key":"10.1016\/j.intimp.2020.107245_b0800","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.antiviral.2017.12.015","article-title":"Disulfiram can inhibit mers and sars coronavirus papain-like proteases via different modes","volume":"150","author":"Lin","year":"2018","journal-title":"Antiviral Res."},{"key":"10.1016\/j.intimp.2020.107245_b0805","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.antiviral.2014.12.011","article-title":"Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus","volume":"115","author":"Cheng","year":"2015","journal-title":"Antiviral Res."},{"issue":"6","key":"10.1016\/j.intimp.2020.107245_b0810","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jinf.2013.09.029","article-title":"Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus","volume":"67","author":"Chan","year":"2013","journal-title":"J. Infect."},{"issue":"12","key":"10.1016\/j.intimp.2020.107245_b0815","doi-asserted-by":"crossref","first-page":"e00023","DOI":"10.1128\/JVI.00023-19","article-title":"High-throughput screening and identification of potent broad-spectrum inhibitors of coronaviruses","volume":"93","author":"Shen","year":"2019","journal-title":"J. Virol."},{"issue":"Pt 3","key":"10.1016\/j.intimp.2020.107245_b0820","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1099\/vir.0.061911-0","article-title":"Interferon-\u03b2 and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays","volume":"95","author":"Hart","year":"2014","journal-title":"J. General Virol."},{"issue":"12","key":"10.1016\/j.intimp.2020.107245_b0825","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1093\/infdis\/jiv392","article-title":"Treatment with lopinavir\/ritonavir or interferon-\u03b21b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset","volume":"212","author":"Chan","year":"2015","journal-title":"J. Infect. Dis."},{"issue":"12","key":"10.1016\/j.intimp.2020.107245_b0830","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1093\/jac\/dkw338","article-title":"A review of treatment modalities for Middle East respiratory syndrome","volume":"71","author":"Mo","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"issue":"1","key":"10.1016\/j.intimp.2020.107245_b0835","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s12879-016-1492-4","article-title":"Treatment outcomes for patients with Middle Eastern Respiratory Syndrome Coronavirus (MERS CoV) infection at a coronavirus referral center in the Kingdom of Saudi Arabia","volume":"16","author":"Al Ghamdi","year":"2016","journal-title":"BMC Infect. Dis."},{"issue":"1","key":"10.1016\/j.intimp.2020.107245_b0840","doi-asserted-by":"crossref","first-page":"32","DOI":"10.5021\/ad.2015.27.1.32","article-title":"Synergistic inhibition of tumor necrosis factor-alpha-stimulated pro-inflammatory cytokine expression in HaCaT cells by a combination of rapamycin and mycophenolic acid","volume":"27","author":"Kim","year":"2015","journal-title":"Ann. Dermatol."},{"issue":"10","key":"10.1016\/j.intimp.2020.107245_b0845","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/ni.1645","article-title":"Toll-like receptor\u2013mediated induction of type I interferon in plasmacytoid dendritic cells requires the rapamycin-sensitive PI (3) K-mTOR-p70S6K pathway","volume":"9","author":"Cao","year":"2008","journal-title":"Nat. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2020.107245_b0850","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.jhep.2014.05.026","article-title":"Rapamycin and everolimus facilitate hepatitis E virus replication: revealing a basal defense mechanism of PI3K-PKB-mTOR pathway","volume":"61","author":"Zhou","year":"2014","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.intimp.2020.107245_b0855","first-page":"1","article-title":"Rapamycin adjuvant and exacerbation of severe influenza in an experimental mouse model","volume":"7","author":"Huang","year":"2017","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.intimp.2020.107245_b0860","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.bbmt.2006.05.014","article-title":"Ex vivo rapamycin generates Th1\/Tc1 or Th2\/Tc2 Effector T cells with enhanced in vivo function and differential sensitivity to post-transplant rapamycin therapy","volume":"12","author":"Jung","year":"2006","journal-title":"Biol. Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.intimp.2020.107245_b0865","doi-asserted-by":"crossref","DOI":"10.4238\/gmr.15027511","article-title":"Rapamycin enhances IFN-gamma and IL-4 production in co-culture of gdelta T and dendritic cells from mice with lipopolysaccharide-induced acute lung injury","volume":"15","author":"Chen","year":"2016","journal-title":"Genet. Mol. Res."},{"issue":"2","key":"10.1016\/j.intimp.2020.107245_b0870","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1128\/AAC.03659-14","article-title":"Antiviral potential of ERK\/MAPK and PI3K\/AKT\/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal kinome analysis","volume":"59","author":"Kindrachuk","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"issue":"8","key":"10.1016\/j.intimp.2020.107245_b0875","doi-asserted-by":"crossref","first-page":"6511","DOI":"10.18632\/aging.103001","article-title":"COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection?","volume":"12","author":"Sargiacomo","year":"2020","journal-title":"Aging (Albany NY)"},{"issue":"268","key":"10.1016\/j.intimp.2020.107245_b0880","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3009892","article-title":"mTOR inhibition improves immune function in the elderly","volume":"6","author":"Mannick","year":"2014","journal-title":"Sci. Transl. Med."},{"issue":"3","key":"10.1016\/j.intimp.2020.107245_b0885","article-title":"Inhaled biguanides and mTOR inhibition for influenza and coronavirus","volume":"2","author":"Lehrer","year":"2020","journal-title":"World Acad. Sci. J."},{"issue":"1","key":"10.1016\/j.intimp.2020.107245_b0890","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/irv.12421","article-title":"Antiviral activity of aspirin against RNA viruses of the respiratory tract\u2014an in vitro study","volume":"11","author":"Glatthaar-Saalm\u00fcller","year":"2017","journal-title":"Influenza Other Respir. Viruses"},{"issue":"1","key":"10.1016\/j.intimp.2020.107245_b0895","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1128\/AAC.31.1.114","article-title":"Effect of acetyl salicylic acid on production and action of leukocyte-derived interferons","volume":"31","author":"Yousefi","year":"1987","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.intimp.2020.107245_b0900","first-page":"26","article-title":"The regulation of interferon production by aspirin, other inhibitors of the cyclooxygenase pathway and agents influencing calcium channel flux","volume":"65","author":"Cesario","year":"1989","journal-title":"Bull. N. Y. Acad. Med."},{"issue":"6","key":"10.1016\/j.intimp.2020.107245_b0905","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/cgt.2013.29","article-title":"Aspirin enhances IFN-\u03b1-induced growth inhibition and apoptosis of hepatocellular carcinoma via JAK1\/STAT1 pathway","volume":"20","author":"Li","year":"2013","journal-title":"Cancer Gene Ther."},{"issue":"6485","key":"10.1016\/j.intimp.2020.107245_b0910","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1126\/science.abb8034","article-title":"Misguided drug advice for COVID-19","volume":"367","author":"FitzGerald","year":"2020","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.intimp.2020.107245_b0915","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1177\/135965350601100803","article-title":"Indomethacin has a potent antiviral activity against SARS coronavirus","volume":"11","author":"Amici","year":"2006","journal-title":"Antiviral Therapy"},{"issue":"9","key":"10.1016\/j.intimp.2020.107245_b0920","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00125-017-4342-z","article-title":"The mechanisms of action of metformin","volume":"60","author":"Rena","year":"2017","journal-title":"Diabetologia"},{"issue":"9","key":"10.1016\/j.intimp.2020.107245_b0925","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1007\/s00125-013-2991-0","article-title":"Molecular mechanism of action of metformin: old or new insights?","volume":"56","author":"Rena","year":"2013","journal-title":"Diabetologia"},{"issue":"3","key":"10.1016\/j.intimp.2020.107245_b0930","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.tips.2020.01.003","article-title":"Context-dependent pharmacological effects of metformin on the immune system","volume":"41","author":"Marcucci","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"issue":"4","key":"10.1016\/j.intimp.2020.107245_b0935","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1080\/07435800.2018.1460605","article-title":"Suppressive effects of metformin on T-helper 1-related chemokines expression in the human monocytic leukemia cell line THP-1","volume":"43","author":"Chen","year":"2018","journal-title":"Endocr. Res."},{"issue":"6","key":"10.1016\/j.intimp.2020.107245_b0940","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s10522-018-9771-7","article-title":"Reversing the immune ageing clock: lifestyle modifications and pharmacological interventions","volume":"19","author":"Duggal","year":"2018","journal-title":"Biogerontology"},{"key":"10.1016\/j.intimp.2020.107245_b0945","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.25958","article-title":"Metformin and COVID-19: a novel deal of an Old Drug","author":"El-Arabey","year":"2020","journal-title":"J. Med. Virol."},{"issue":"4","key":"10.1016\/j.intimp.2020.107245_b0950","doi-asserted-by":"crossref","first-page":"404","DOI":"10.3390\/v12040404","article-title":"In silico discovery of candidate drugs against covid-19","volume":"12","author":"Cava","year":"2020","journal-title":"Viruses"},{"issue":"4","key":"10.1016\/j.intimp.2020.107245_b0955","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.3892\/ijo.2016.3650","article-title":"Fluoxetine regulates cell growth inhibition of interferon-\u03b1","volume":"49","author":"Lin","year":"2016","journal-title":"Int. J. Oncol."},{"issue":"2","key":"10.1016\/j.intimp.2020.107245_b0960","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/00004714-200104000-00012","article-title":"Anti-inflammatory effects of antidepressants through suppression of the interferon-\u03b3\/interleukin-10 production ratio","volume":"21","author":"Kubera","year":"2001","journal-title":"J. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2020.107245_b0965","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/hup.191","article-title":"The immunoregulatory effects of antidepressants","volume":"16","author":"Maes","year":"2001","journal-title":"Human Psychopharmacol.: Clin. Exp."},{"issue":"2","key":"10.1016\/j.intimp.2020.107245_b0970","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.pupt.2011.11.001","article-title":"Effect of verapamil on bronchial goblet cells of asthma: an experimental study on sensitized animals","volume":"25","author":"Khakzad","year":"2012","journal-title":"Pulm. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.intimp.2020.107245_b0975","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1253\/circj.CJ-09-0467","article-title":"Calcium channel blockers differentially modulate cytokine production by peripheral blood mononuclear cells","volume":"74","author":"Matsumori","year":"2010","journal-title":"Circ. J."},{"issue":"4","key":"10.1016\/j.intimp.2020.107245_b0980","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.neuropharm.2012.05.033","article-title":"Inhibition of human astrocyte and microglia neurotoxicity by calcium channel blockers","volume":"63","author":"Hashioka","year":"2012","journal-title":"Neuropharmacology"},{"issue":"11","key":"10.1016\/j.intimp.2020.107245_b0985","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0080304","article-title":"Fluvastatin interferes with hepatitis C virus replication via microtubule bundling and a doublecortin-like kinase-mediated mechanism","volume":"8","author":"Ali","year":"2013","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.intimp.2020.107245_b0990","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1053\/j.gastro.2010.08.055","article-title":"Statin therapy improves sustained virologic response among diabetic patients with chronic hepatitis C","volume":"140","author":"Rao","year":"2011","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.intimp.2020.107245_b0995","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1002\/jmv.23682","article-title":"Simvastatin treatment showed no prophylactic effect in influenza virus-infected mice","volume":"85","author":"Gl\u00fcck","year":"2013","journal-title":"J. Med. Virol."},{"issue":"6","key":"10.1016\/j.intimp.2020.107245_b1000","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1189\/jlb.0713413","article-title":"Simvastatin attenuates rhinovirus-induced interferon and CXCL10 secretion from monocytic cells in vitro","volume":"95","author":"Wickert","year":"2014","journal-title":"J. Leukoc. Biol."},{"issue":"3","key":"10.1016\/j.intimp.2020.107245_b1005","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ejps.2009.07.004","article-title":"Evaluation of the efficacy and safety of a statin\/caffeine combination against H5N1, H3N2 and H1N1 virus infection in BALB\/c mice","volume":"38","author":"Liu","year":"2009","journal-title":"Eur. J. Pharm. Sci."},{"issue":"5","key":"10.1016\/j.intimp.2020.107245_b1010","doi-asserted-by":"crossref","first-page":"763","DOI":"10.3109\/08923973.2011.653648","article-title":"The impact of prophylactic antiviral agents and statin administration on graft longevity in kidney allograft recipients","volume":"34","author":"Rahal","year":"2012","journal-title":"Immunopharmacol. Immunotoxicol."},{"issue":"11","key":"10.1016\/j.intimp.2020.107245_b1015","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1002\/jmv.23682","article-title":"Simvastatin treatment showed no prophylactic effect in influenza virus-infected mice","volume":"85","author":"Gluck","year":"2013","journal-title":"J. Med. Virol."},{"issue":"4","key":"10.1016\/j.intimp.2020.107245_b1020","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1080\/01616412.2018.1558000","article-title":"Statin treatment before stroke reduces pro-inflammatory cytokine levels after stroke","volume":"41","author":"Schultz","year":"2019","journal-title":"Neurol. Res."},{"issue":"1","key":"10.1016\/j.intimp.2020.107245_b1025","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ijcard.2008.10.044","article-title":"Modulation of human T cells signaling transduction by lovastatin","volume":"140","author":"Cheng","year":"2010","journal-title":"Int. J. Cardiol."},{"issue":"3","key":"10.1016\/j.intimp.2020.107245_b1030","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/S1734-1140(13)71056-9","article-title":"Lymphocyte-suppressing action of simvastatin in patients with isolated hypertriglyceridemia","volume":"65","author":"Krysiak","year":"2013","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.intimp.2020.107245_b1035","article-title":"Simvastatin acts as an inhibitor of interferon gamma-induced cycloxygenase-2 expression in human THP-1 cells, but not in murine RAW264. 7 cells","author":"Lee","year":"2009","journal-title":"Biocell"},{"issue":"5","key":"10.1016\/j.intimp.2020.107245_b1040","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/phar.2397","article-title":"Considerations for statin therapy in patients with COVID-19","volume":"40","author":"Dashti-Khavidaki","year":"2020","journal-title":"Pharmacotherapy: J. Human Pharmacol. Drug Therapy"},{"issue":"3","key":"10.1016\/j.intimp.2020.107245_b1045","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/resp.12926","article-title":"Simvastatin alleviates airway inflammation and remodelling through up-regulation of autophagy in mouse models of asthma","volume":"22","author":"Gu","year":"2017","journal-title":"Respirology"},{"issue":"3","key":"10.1016\/j.intimp.2020.107245_b1050","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.pharmthera.2006.02.002","article-title":"Immunomodulatory effects of caffeine: friend or foe?","volume":"111","author":"Horrigan","year":"2006","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.intimp.2020.107245_b1055","article-title":"Caffeine-enhanced anti-tumor immune response through decreased expression of PD1 on infiltrated cytotoxic T lymphocytes","volume":"859","author":"Tej","year":"2019","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2020.107245_b1060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-35094-z","article-title":"Modulation of salivary cytokines in response to alcohol, tobacco and caffeine consumption: a pilot study","volume":"8","author":"Sheth","year":"2018","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.intimp.2020.107245_b1065","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/jaoac\/93.2.492","article-title":"Quantification of glycyrrhizin in Glycyrrhiza glabra extract by validated HPTLC densitometry","volume":"93","author":"Gantait","year":"2010","journal-title":"J. AOAC Int."},{"issue":"11","key":"10.1016\/j.intimp.2020.107245_b1070","doi-asserted-by":"crossref","first-page":"4112","DOI":"10.1105\/tpc.110.082685","article-title":"Triterpene functional genomics in licorice for identification of CYP72A154 involved in the biosynthesis of glycyrrhizin","volume":"23","author":"Seki","year":"2011","journal-title":"Plant Cell"},{"issue":"37","key":"10.1016\/j.intimp.2020.107245_b1075","doi-asserted-by":"crossref","first-page":"14204","DOI":"10.1073\/pnas.0803876105","article-title":"Licorice \u03b2-amyrin 11-oxidase, a cytochrome P450 with a key role in the biosynthesis of the triterpene sweetener glycyrrhizin","volume":"105","author":"Seki","year":"2008","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"3","key":"10.1016\/j.intimp.2020.107245_b1080","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0166-3542(87)90001-5","article-title":"Inhibitory effect of glycyrrhizin on the in vitro infectivity and cytopathic activity of the human immunodeficiency virus [HIV (HTLV-III\/LAV)]","volume":"7","author":"Ito","year":"1987","journal-title":"Antiviral Res."},{"issue":"6","key":"10.1016\/j.intimp.2020.107245_b1085","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/0166-3542(88)90047-2","article-title":"Mechanism of inhibitory effect of glycyrrhizin on replication of human immunodeficiency virus (HIV)","volume":"10","author":"Ito","year":"1988","journal-title":"Antiviral Res."},{"key":"10.1016\/j.intimp.2020.107245_b1090","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.phytochem.2014.03.004","article-title":"The effect of drought stress on the expression of key genes involved in the biosynthesis of triterpenoid saponins in liquorice (Glycyrrhiza glabra)","volume":"103","author":"Nasrollahi","year":"2014","journal-title":"Phytochemistry"},{"issue":"13","key":"10.1016\/j.intimp.2020.107245_b1095","doi-asserted-by":"crossref","first-page":"1906206","DOI":"10.1002\/smll.201906206","article-title":"Glycyrrhizic-acid-based carbon dots with high antiviral activity by multisite inhibition mechanisms","volume":"16","author":"Tong","year":"2020","journal-title":"Small"},{"issue":"5","key":"10.1016\/j.intimp.2020.107245_b1100","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/eji.200535503","article-title":"IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis","volume":"36","author":"Wolk","year":"2006","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.intimp.2020.107245_b1105","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.cyto.2016.06.020","article-title":"Correlation of IL-12, IL-22, and IL-23 in patients with psoriasis and metabolic syndrome. Preliminary report","volume":"85","author":"Brito-Luna","year":"2016","journal-title":"Cytokine"},{"issue":"4","key":"10.1016\/j.intimp.2020.107245_b1110","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.intimp.2012.08.013","article-title":"Glycyrrhizin regulates CD4+ T cell response during liver fibrogenesis via JNK, ERK and PI3K\/AKT pathway","volume":"14","author":"Tu","year":"2012","journal-title":"Int. Immunopharmacol."},{"issue":"2","key":"10.1016\/j.intimp.2020.107245_b1115","first-page":"1291","article-title":"Treatment of psoriasis by compound glycyrrhizin injection and its effects on peripheral blood Th17 cell proportion and IL-22 concentration","volume":"11","author":"Xiao","year":"2018","journal-title":"Int. J. Clin. Exp. Med."},{"issue":"8","key":"10.1016\/j.intimp.2020.107245_b1120","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.3390\/ijms21082961","article-title":"Glycyrrhizin inhibits PEDV infection and proinflammatory cytokine secretion via the HMGB1\/TLR4-MAPK p38 pathway","volume":"21","author":"Gao","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.intimp.2020.107245_b1125","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1007\/s00705-017-3259-7","article-title":"Glycyrrhizin inhibits porcine epidemic diarrhea virus infection and attenuates the proinflammatory responses by inhibition of high mobility group box-1 protein","volume":"162","author":"Huan","year":"2017","journal-title":"Arch. Virol."},{"issue":"2","key":"10.1016\/j.intimp.2020.107245_b1130","doi-asserted-by":"crossref","first-page":"57","DOI":"10.6000\/1927-3037.2015.04.02.2","article-title":"The effects and mechanism of yinqiao powder on upper respiratory tract infection","volume":"4","author":"Liu","year":"2015","journal-title":"Int. J. Biotechnol. Wellness Indust."},{"issue":"1","key":"10.1016\/j.intimp.2020.107245_b1135","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13020-018-0199-4","article-title":"Effects of different principles of traditional Chinese medicine treatment on TLR7\/NF-\u03baB signaling pathway in influenza virus infected mice","volume":"13","author":"Fu","year":"2018","journal-title":"Chinese Med."},{"issue":"9374","key":"10.1016\/j.intimp.2020.107245_b1140","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1016\/S0140-6736(03)13615-X","article-title":"Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus","volume":"361","author":"Cinatl","year":"2003","journal-title":"The Lancet"},{"key":"10.1016\/j.intimp.2020.107245_b1145","article-title":"Liquorice may tackle SARS","author":"Pilcher","year":"2003","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.intimp.2020.107245_b1150","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1527-3466.2001.tb00068.x","article-title":"Cardiovascular actions of berberine","volume":"19","author":"Lau","year":"2001","journal-title":"Cardiovasc. Drug Rev."},{"issue":"2","key":"10.1016\/j.intimp.2020.107245_b1155","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3810\/hp.2012.04.970","article-title":"Antidiabetic properties of berberine: from cellular pharmacology to clinical effects","volume":"40","author":"Cicero","year":"2012","journal-title":"Hospital Practice"},{"issue":"3","key":"10.1016\/j.intimp.2020.107245_b1160","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1046\/j.1365-2567.2003.01673.x","article-title":"Induction of interleukin-12 production in mouse macrophages by berberine, a benzodioxoloquinolizine alkaloid, deviates CD4+ T cells from a Th2 to a Th1 response","volume":"109","author":"Kim","year":"2003","journal-title":"Immunology"},{"issue":"2","key":"10.1016\/j.intimp.2020.107245_b1165","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.canlet.2003.09.002","article-title":"The anti-inflammatory potential of berberine in vitro and in vivo","volume":"203","author":"Kuo","year":"2004","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.intimp.2020.107245_b1170","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jcv.2007.10.011","article-title":"In vitro inhibition of coronavirus replications by the traditionally used medicinal herbal extracts, Cimicifuga rhizoma, Meliae cortex, Coptidis rhizoma, and Phellodendron cortex","volume":"41","author":"Kim","year":"2008","journal-title":"J. Clin. Virol."},{"issue":"12","key":"10.1016\/j.intimp.2020.107245_b1175","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1007\/s00705-010-0779-9","article-title":"Anti-herpes simplex virus effects of berberine from Coptidis rhizoma, a major component of a Chinese herbal medicine, Ching-Wei-San","volume":"155","author":"Chin","year":"2010","journal-title":"Arch. Virol."},{"key":"10.1016\/j.intimp.2020.107245_b1180","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.antiviral.2015.12.012","article-title":"Discovery of berberine, abamectin and ivermectin as antivirals against chikungunya and other alphaviruses","volume":"126","author":"Varghese","year":"2016","journal-title":"Antiviral Res."},{"key":"10.1016\/j.intimp.2020.107245_b1185","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.phymed.2018.09.025","article-title":"Berberine inhibits hepatitis C virus entry by targeting the viral E2 glycoprotein","volume":"53","author":"Hung","year":"2019","journal-title":"Phytomedicine"},{"issue":"22","key":"10.1016\/j.intimp.2020.107245_b1190","doi-asserted-by":"crossref","first-page":"7940","DOI":"10.1016\/j.bmc.2010.09.035","article-title":"Biflavonoids from Torreya nucifera displaying SARS-CoV 3CLpro inhibition","volume":"18","author":"Ryu","year":"2010","journal-title":"Bioorg. Med. Chem."},{"issue":"2","key":"10.1016\/j.intimp.2020.107245_b1195","first-page":"81","article-title":"The battle against COVID-19: Where do we stand now?","volume":"45","author":"Negahdaripour","year":"2020","journal-title":"Iran. J. Med. Sci."},{"issue":"8","key":"10.1016\/j.intimp.2020.107245_b1200","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/nm1080","article-title":"An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus","volume":"10","author":"Traggiai","year":"2004","journal-title":"Nat. Med."},{"issue":"139","key":"10.1016\/j.intimp.2020.107245_b1205","doi-asserted-by":"crossref","first-page":"139","DOI":"10.12688\/wellcomeopenres.15927.1","article-title":"Antibody testing for COVID-19: a report from the National COVID Scientific Advisory Panel","volume":"5","author":"Adams","year":"2020","journal-title":"Wellcome Open Res."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576920337127?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576920337127?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:28:38Z","timestamp":1761586118000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576920337127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":241,"alternative-id":["S1567576920337127"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2020.107245","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interferon-inducer antivirals: Potential candidates to combat COVID-19","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2020.107245","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107245"}}